Trials / Completed
CompletedNCT00374855
A Study in People With Mild Hypertension
Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 153 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PPAR alpha | |
| DRUG | Hydrochlorothiazide | |
| DRUG | Placebo |
Timeline
- Start date
- 2006-09-01
- Completion
- 2006-11-01
- First posted
- 2006-09-12
- Last updated
- 2007-05-15
Locations
10 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00374855. Inclusion in this directory is not an endorsement.